Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972 · cited 1×
“Despite high expectations, progress in the development of therapeutic cancer vaccines has been rather slow [147].”
BackgroundCancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“The effectiveness of adoptive tumor immunotherapy has been significantly strengthened by the application of re-directed tumorreactive T cells [136].”
BackgroundKobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953 · cited 1×
“Based on its actions, IL-12 was initially designated as “cytotoxic lymphocyte maturation factor” [1] and “natural killer cell stimulatory factor” [2].”
BackgroundAdoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · cited 1×
“Over time, much progress has been made in this field [167], due to • optimization of the treatment protocol (e.”
BackgroundAdoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659 · cited 1×
“The major limitation was a short half-time of circulation of the infused cells and their poor homing to the tumor (for review, see [166]).”
BackgroundReversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,634 · cited 5×
“Advantages of IL-15 in tumor immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells [10–12] and CD8 T cells [13–16], and promoting a persistent immune response through its action on memory T cells [16–20].”
BackgroundInfluentialCloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor
Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., et al. (1994) · Science · doi:10.1126/science.8178155 · Cited by 1,422 · cited 1×
“Interleukin 15 (IL-15) was discovered as another T cell growth factor [1] and belongs to the family of the common gamma chain (gc) or four-helix-bundle cytokines, which includes IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.”
BackgroundFyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391 · cited 1×
“001 complete responses were achieved in only a small percentage of patients given high-dose IL-2 therapy [4].”
BackgroundIL-15 Receptor Maintains Lymphoid Homeostasis by Supporting Lymphocyte Homing and Proliferation
Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S., & Ma, A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80664-0 · Cited by 1,299 · cited 3×
“For CD8 T cells, IL-15 is just one of the more important factors that stimulate their activation [13], extensive proliferation [13,14,71], differentiation into effector cells [14,15],”
BackgroundPotent and Selective Stimulation of Memory-Phenotype CD8+ T Cells In Vivo by IL-15
Zhang, X., Sun, S., Hwang, I., Tough, D. F., & Sprent, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80564-6 · Cited by 1,245 · cited 1×
“memory CD4 T cells in non-human primates [18], but it does not do so in mice [101], or only in combination with IL-7 as an accessory”
BackgroundAntitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197 · cited 1×
“This cytokine has been successfully applied in dozens of experimental models in mice involving both solid tumors and hematologic malignancies including poorly immunogenic tumors [56–60].”
BackgroundRequirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A. A., Doherty, P. C., Grosveld, G. C., et al. (1996) · Nature · doi:10.1038/382171a0 · Cited by 1,180 · cited 1×
“Among the STAT family of transcription factors, STAT4 is considered to be the most specific mediator of cellular responses elicited by IL-12 [13].”
BackgroundThe biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178 · cited 3×
“Thus, IL-15 seems to function under normal circumstances as a cell-bound cytokine and is trans-presented to responding cells together with co-stimulatory signals ([46] and reviewed in [55]), although the dominance of trans-presentation of IL-15 to CD8 T cells has recently been called into question [56].”
BackgroundRosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 969 · cited 1×
“Central memory CD8 T cells have been demonstrated to exert stronger antitumor activity in tumor-bearing mice, as compared with effector memory CD8 T cells [100].”
BackgroundGattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958 · cited 2×
“influences their differentiation, at least as far as the response against tumor-associated antigens is concerned [15,97].”
BackgroundCytotoxic T lymphocytes: all roads lead to death
Barry, M., & Bleackley, R. C. (2002) · Nature Reviews Immunology · doi:10.1038/nri819 · Cited by 933 · cited 1×
“granule- or FAS-mediated pathways (reviewed in [95]).”
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Dubois, S., Mariner, J., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 913 · cited 3×
“Thus, IL-15 seems to function under normal circumstances as a cell-bound cytokine and is trans-presented to responding cells together with co-stimulatory signals ([46] and reviewed in [55]), although the dominance of trans-presentation of IL-15 to CD8 T cells has recently been called into question [56].”
BackgroundCytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Lin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752 · cited 2×
“IL-15 can trigger a cytokine cascade including TNF-a, IL-1, IL-6, GM-CSF, and proinflammatory chemokines [61,78].”
BackgroundSynergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
Zeng, R., Spolski, R., Finkelstein, S. E., Oh, S., Kovanen, P. E., Hinrichs, C. S., Pise-Masison, C. A., Radonovich, M. F., Brady, J. N., Restifo, N. P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041057 · Cited by 727 · cited 3×
“Combined use with IL-7 [130], IL-12 [120,131], and IL-21 [126,129]”
BackgroundMethodInhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722 · cited 1×
“Judah Folkman [40].”
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701 · cited 1×
“In 53 % patients, there was evidence of systemic response and three patients experienced complete response (of note, one of these patients was additionally treated with dacarbazine) [165].”
BackgroundHeufler, C., Koch, F., Stanzl, U., Topar, G., Wysocka, M., Trinchieri, G., Enk, A., Steinman, R. M., Romani, N., & Schuler, G. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260323 · Cited by 700 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundPegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678 · cited 1×
“Moreover, IL-12 has strengthened the antitumor activity of adoptive therapy with targeted T cells engineered to secrete IL-12 [104] or therapy with oncolytic Herpes simplex virus expressing IL-12 [105].”
BackgroundAtkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 672
Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y. C., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L., Truitt, T., & Chizzonite, R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6808 · Cited by 670 · cited 1×
“Based on its actions, IL-12 was initially designated as “cytotoxic lymphocyte maturation factor” [1] and “natural killer cell stimulatory factor” [2].”
BackgroundGiri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., DuBose, R., Cosman, D., Park, L. S., & Anderson, D. M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00035.x · Cited by 628 · cited 2×
“IL-15 binds to IL-2/15Rbgc with intermediate affinity (Ka 10 9 M) (reviewed in [47]), and, unexpectedly, IL-15Ra joining IL-2/15Rbgc complex does not further increase this affinity [43,48].”
BackgroundInterleukin-12: Biological Properties and Clinical Application
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G., & Anichini, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0776 · Cited by 601
Functional Activation of Jak1 and Jak3 by Selective Association with IL-2 Receptor Subunits
Miyazaki, T., Kawahara, A., Fujii, H., Nakagawa, Y., Minami, Y., Liu, Z.-J., Oishi, I., Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., et al. (1994) · Science · doi:10.1126/science.7973659 · Cited by 589 · cited 1×
“IL-2/15Rb associates with JAK1 phosphorylating STAT3, and the common g chain of this receptor associates with JAK3 phosphorylating STAT5 [60,61].”
BackgroundIL-15 trans-presentation promotes human NK cell development and differentiation in vivo
Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082013 · Cited by 577 · cited 1×
“IL-15 is a key regulator of NK cell development, activation, proliferation and survival [10–12,90,91,103], and accelerates their reconstitution following bone marrow transplantation [104].”
BackgroundIL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577 · cited 2×
“The capacity of IL-15 used alone [141] or in combination with IL-21 [128] or chemotherapy [133] to further enhance efficacy of adoptive immunotherapy seems to be particularly promising.”
BackgroundControl of Regulatory T Cell Lineage Commitment and Maintenance
Josefowicz, S. Z., & Rudensky, A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.009 · Cited by 571 · cited 2×
“regulatory FoxP3 Tab cells [159,160] in a manner similar to IL-7 [22] but less potent than IL-2 [8,22].”
BackgroundHoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Schulz, O., Edwards, A. D., Schito, M., Aliberti, J., Manickasingham, S., Sher, A., & Reis e Sousa, C. (2000) · Immunity · doi:10.1016/s1074-7613(00)00045-5 · Cited by 561
Rosenstein, M., Ettinghausen, S. E., & Rosenberg, S. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.5.1735 · Cited by 530
Schluns, K. S., Williams, K., Ma, A., Zheng, X. X., & Lefrançois, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4827 · Cited by 521 · cited 1×
“It also induces proliferation of naı̈ve CD8 and memory CD4 and CD8 T cells [13,52], promoting development of the primary response of effector CD8 T cells [52,72], and makes both CD4 and CD8 T cells resistant to the action of Treg cells [23].”
BackgroundKinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513 · cited 1×
“IL-2, -7, and -15 also induce expression of PD-1L in these cells [163].”
BackgroundIL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Hinrichs, C. S., Spolski, R., Paulos, C. M., Gattinoni, L., Kerstann, K. W., Palmer, D. C., Klebanoff, C. A., Rosenberg, S. A., Leonard, W. J., & Restifo, N. P. (2008) · Blood · doi:10.1182/blood-2007-09-113050 · Cited by 462 · cited 3×
“influences their differentiation, at least as far as the response against tumor-associated antigens is concerned [15,97].”
BackgroundMattei, F., Schiavoni, G., Belardelli, F., & Tough, D. F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1179 · Cited by 459 · cited 3×
“dendritic cells, participates in their activation, proliferation and differentiation [33,75,76], promoting expression of MHC class II,”
BackgroundWaldmann, T. A. (1986) · Science · doi:10.1126/science.3008337 · Cited by 453 · cited 1×
“IL-15 binds to IL-2/15Rbgc with intermediate affinity (Ka 10 9 M) (reviewed in [47]), and, unexpectedly, IL-15Ra joining IL-2/15Rbgc complex does not further increase this affinity [43,48].”
BackgroundSporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445 · cited 1×
“blocking the immune response against TAAs [109], the development of immunologic tolerance towards TAAs [110], and the”
BackgroundTagaya, Y., Bamford, R. N., DeFilippis, A. P., & Waldmann, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80246-0 · Cited by 440
IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation.
Armitage, R. J., Macduff, B. M., Eisenman, J., Paxton, R., & Grabstein, K. H. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.2.483 · Cited by 434 · cited 2×
“polyclonal IgM, IgG1 and IgA immunoglobulins [74].”
BackgroundIL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
Marks-Konczalik, J., Dubois, S., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., & Tagaya, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200363097 · Cited by 433 · cited 1×
“cell death [158], one of the peripheral mechanisms protecting against autoimmunity.”
BackgroundA potential role for interleukin-15 in the regulation of human natural killer cell survival.
Carson, W. E., Fehniger, T. A., Haldar, S., Eckhert, K., Lindemann, M. J., Lai, C. F., Croce, C. M., Baumann, H., & Caligiuri, M. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119258 · Cited by 419 · cited 2×
“IL-15 is a key regulator of NK cell development, activation, proliferation and survival [10–12,90,91,103], and accelerates their reconstitution following bone marrow transplantation [104].”
BackgroundSustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419 · cited 4×
“Antitumor effects of IL-12 were evaluated in various treatment schedules: intravenous [121–123] versus subcutaneous [124, 125] or even intraperitoneal application [126], daily and five consecutive injections every 3 weeks [121, 122, 127], or at 1 [124, 125, 128], 2 [123], or 3 [129] All-trans-retinoic acid in liposome…”
BackgroundInfluentialCoughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1555 · Cited by 415
Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity.
Ling, P., Gately, M. K., Gubler, U., Stern, A. S., Lin, P., Hollfelder, K., Su, C., Pan, Y. C. E., & Hakimi, J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.116 · Cited by 399 · cited 1×
“Contrary to the heterodimeric form, IL-12-p40/p40 homodimer acts mostly as a competitive suppressant of IL-12-p70 actions [10].”
BackgroundIL-21 in Synergy with IL-15 or IL-18 Enhances IFN-γ Production in Human NK and T Cells
Strengell, M., Matikainen, S., Sirén, J., Lehtonen, A., Foster, D., Julkunen, I., & Sareneva, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5464 · Cited by 394 · cited 2×
“Therefore, IL-15 has been used in experimental tumor therapy in combination with IL-21 [19,126–128], but also combined with”
BackgroundMethodInterleukin 12 a Key Immunoregulatory Cytokine in Infection Applications
Hamza, T., Barnett, J. B., & Li, B. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11030789 · Cited by 383 · cited 1×
“Following the discovery of IL-12, three other members (IL-23, IL-27, and IL-35) have been added to the IL-12 family and shown to play critical roles in Th1 cell functions (reviewed in [11]).”
MethodInfluentialFehniger, T. A., Suzuki, K., Ponnappan, A., VanDeusen, J. B., Cooper, M. A., Florea, S. M., Freud, A. G., Robinson, M. L., Durbin, J., & Caligiuri, M. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.219 · Cited by 373
Anderson, D. M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, A., Giri, J., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29862 · Cited by 372
Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo
Stoklasek, T. A., Schluns, K. S., & Lefrançois, L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6072 · Cited by 366 · cited 5×
“15 to IL-15 receptors, its activity can be significantly potentiated when IL-15 is pre-associated with IL-15Ra as a IL-15/IL-15Ra [52,124] or IL-15/IL-15Ra-IgG1-Fc [12] complex.”
BackgroundInfluentialCarson, W. E., Ross, M. E., Baiocchi, R. A., Marien, M. J., Boiani, N., Grabstein, K., & Caligiuri, M. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118321 · Cited by 348 · cited 1×
“cells, but not T cells ([27,28] and reviewed in [24]).”
BackgroundIL-15 Promotes the Survival of Naive and Memory Phenotype CD8+ T Cells
Berard, M., Brandt, K., Paus, S. B., & Tough, D. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5018 · Cited by 343 · cited 2×
“Advantages of IL-15 in tumor immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells [10–12] and CD8 T cells [13–16], and promoting a persistent immune response through its action on memory T cells [16–20].”
BackgroundIL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342 · cited 2×
“These are potent antiangiogenic effects via induction of antiangiogenic cytokine and chemokine production [32], remodeling of the peritumoral extracellular matrix and tumor stroma [33], reprogramming of myeloid-derived suppressor cells [34], and changes in processing and increasing expression of MHC class I molecules…”
BackgroundTwelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341 · cited 2×
“cells, but not T cells ([27,28] and reviewed in [24]).”
BackgroundRoberts, A. I., Lee, L., Schwarz, E., Groh, V., Spies, T., Ebert, E. C., & Jabri, B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5527 · Cited by 335
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332 · cited 1×
“Finally, after several months of suspension, clinical trials were resumed in several centers [120].”
BackgroundInterleukin-15 protects from lethal apoptosis in vivo
Bulfone-Paus, S., Ungureanu, D., Pohl, T., Lindner, G., Paus, R., Rückert, R., Krause, H., & Kunzendorf, U. (1997) · Nature Medicine · doi:10.1038/nm1097-1124 · Cited by 330 · cited 2×
“It also inhibits apoptosis of neutrophils [81,83], eosinophils [84], Fas-mediated apoptosis of B cells [85] and T cells”
BackgroundNizzoli, G., Krietsch, J., Weick, A., Steinfelder, S., Facciotti, F., Gruarin, P., Bianco, A., Steckel, B., Moro, M., Crosti, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-495424 · Cited by 330 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundSangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320 · cited 1×
“Adenovirus encoding IL-12 Intratumoral Liver, colorectal, pancreatic cancer [145]”
BackgroundMortier, E., Woo, T., Advincula, R., Gozalo, S., & Ma, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071913 · Cited by 316 · cited 2×
“Binding of IL-15 with sushi domain of IL-15Ra [42] occurs intracellularly, and IL-15Ra chaperons and shuttles IL-15 from the endoplasmic reticulum to the cell membrane [45].”
BackgroundYang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309 · cited 1×
“A recent study, however, has demonstrated that prolonged treatment with IL-12 can have some detrimental effects on antitumor activity of T cells, by the induction of expression of Tim-3 molecule in T cells [38].”
BackgroundMonoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 307 · cited 1×
“immunotherapy (reviewed in [142]), and their antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), with NK cells serving as the most important effector cells in this mechanism.”
BackgroundChemoattraction of human blood T lymphocytes by interleukin-15.
Wilkinson, P. C., & Liew, F. Y. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1255 · Cited by 290 · cited 1×
“IL-15 has also demonstrated chemotactic activity towards CD4 and CD8 T cells [73].”
Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 285
Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M. F., Sherman, M. L., Witmer, W. K., Rockwell, K. A., Shane, R. B., Lessin, S. R., et al. (1999) · Blood · doi:10.1182/blood.v94.3.902.415k23_902_908 · Cited by 277 · cited 1×
“[151], 10 patients with CTCL, including 3 with Sézary syndrome, were treated with 50, 100, or 300 ng/kg IL-12, subcutaneously or intralesionally twice a week.”
MethodTahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6466 · Cited by 271
Kikuchi, T., Akasaki, Y., Irie, M., Homma, S., Abe, T., & Ohno, T. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620100205 · Cited by 270 · cited 1×
“This adoptive immunotherapy, using either autologous or allogeneic dendritic cells, was exploited in the past in patients with different tumors [170–172]).”
BackgroundHuntington, N. D., Puthalakath, H., Gunn, P., Naik, E., Michalak, E. M., Smyth, M. J., Tabarias, H., Degli-Esposti, M. A., Dewson, G., Willis, S. N., et al. (2007) · Nature Immunology · doi:10.1038/ni1487 · Cited by 268 · cited 2×
“IL-15 is a key regulator of NK cell development, activation, proliferation and survival [10–12,90,91,103], and accelerates their reconstitution following bone marrow transplantation [104].”
BackgroundMoroz, A., Eppolito, C., Li, Q., Tao, J., Clegg, C. H., & Shrikant, P. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.900 · Cited by 268 · cited 1×
“and survival [16] in both antigen-dependent [96] and -independent [14] ways.”
BackgroundNew Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway
Gu, H., Maeda, H., Moon, J. J., Lord, J. D., Yoakim, M., Nelson, B. H., & Neel, B. G. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.19.7109-7120.2000 · Cited by 267 · cited 1×
“It also activates RAS and phosphatidylinositol 3kinase/AKT pathways [66] and induces expression of transcription factors c-FOS, c-JUN, c-MYC, and NF-kB [64,67,68].”
BackgroundInterleukin‐2 in the development and control of inflammatory disease
Hoyer, K. K., Dooms, H., Barron, L., & Abbas, A. K. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00697.x · Cited by 262 · cited 1×
“Furthermore, although IL-2 stimulates proliferation and differentiation of effector T cells, memory CD8T cells and natural killer (NK) cells (reviewed in [7]), strengthening the antitumor immune response, it may also”
BackgroundVang, K. B., Yang, J., Mahmud, S. A., Burchill, M. A., Vegoe, A. L., & Farrar, M. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3285 · Cited by 262
Type I IFNs Inhibit Human Dendritic Cell IL-12 Production and Th1 Cell Development
McRae, B. L., Semnani, R. T., Hayes, M. P., & van Seventer, G. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4298 · Cited by 260 · cited 1×
“Suppression of IL-12 production is mediated by such cytokines as type I IFNs [19], IL-10, and TGF-β [20] as well as by prostaglandin e2 (PGe2) that is produced by various cancers [21].”
BackgroundLucas, M. L., Heller, L., Coppola, D., & Heller, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0601 · Cited by 253 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundMotzer, R. J., Rakhit, A. K., Schwartz, L. H., Olencki, T. E., Malone, T., Sandstrom, K., Nadeau, R., Parmar, H. R., & Bukowski, R. M. (1998) · PubMed · Cited by 251
Safety and immunologic effects of IL-15 administration in nonhuman primates
Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244 · cited 4×
“Both effector and central memory CD8 T cells are stimulated by IL-15 [18–20,98].”
BackgroundInfluentialLee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuge, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3836 · Cited by 244
Shurin, G. V., Tourkova, I. L., Kaneno, R., & Shurin, M. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900734 · Cited by 242
Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 235
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors
Teague, R. M., Sather, B. D., Sacks, J. A., Huang, M. Z., Dossett, M. L., Morimoto, J., Tan, X., Sutton, S. E., Cooke, M. P., Öhlén, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1359 · Cited by 233 · cited 1×
“immunosuppressive action of Tregs [23], and can potentially reverse unresponsiveness of CD8 T cells to tumor cells abrogating tolerance to TAAs [112–114], which was not observed with IL-2 treatment [112].”
BackgroundShibuya, H., Yoneyama, M., Ninomiya-Tsuji, J., Matsumoto, K., & Taniguchi, T. (1992) · Cell · doi:10.1016/0092-8674(92)90533-i · Cited by 231 · cited 1×
“It also activates RAS and phosphatidylinositol 3kinase/AKT pathways [66] and induces expression of transcription factors c-FOS, c-JUN, c-MYC, and NF-kB [64,67,68].”
BackgroundGirard, D., Paquet, M., Paquin, R., & Beaulieu, A. (1996) · Blood · doi:10.1182/blood.v88.8.3176.bloodjournal8883176 · Cited by 229 · cited 2×
“It stimulates NF-kB activation and production of IL-8 in neutrophils and enhances their phagocytic and antimicrobial activity [68,81,82].”
BackgroundIL-12: a key cytokine in immune regulation
Lamont, A. G., & Adorini, L. (1996) · Immunology Today · doi:10.1016/0167-5699(96)30011-x · Cited by 229 · cited 1×
“In this small pilot study, IL-12-producing cells were injected peritumorally once a week [117].”
BackgroundRosenblatt, J., Vasir, B., Uhl, L., Blotta, S., MacNamara, C., Somaiya, P., Wu, Z., Joyce, R., Levine, J. D., Dombagoda, D., et al. (2011) · Blood · doi:10.1182/blood-2010-04-277137 · Cited by 228 · cited 1×
“The therapy induced specific antitumor response and disease stabilization in the majority of patients [173] and, when applied following autologous stem cell transplantation, resulted in the marked development of myeloma-specific T cells and eradication of posttransplant residual disease in some patients [174].”
BackgroundMarkley, J. C., & Sadelain, M. (2010) · Blood · doi:10.1182/blood-2009-09-241398 · Cited by 228 · cited 2×
“Both effector and central memory CD8 T cells are stimulated by IL-15 [18–20,98].”
BackgroundAdenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.
Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., & Chen, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11302 · Cited by 227
Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., & Rodeck, U. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65149-8 · Cited by 227
Immunotherapy of cancer by IL-12-based cytokine combinations
Weiss, J. M., Subleski, J. J., Wigginton, J. M., & Wiltrout, R. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1705 · Cited by 221
Musso, T., Calosso, L., Zucca, M., Millesimo, M., Ravarino, D., Giovarelli, M., Malavasi, F., Ponzi, A. N., Paus, R., & Bulfone-Paus, S. (1999) · Blood · doi:10.1182/blood.v93.10.3531.410k32_3531_3539 · Cited by 220 · cited 1×
“agonists of Toll-like receptors (TLRs) including LPS, doublestranded RNA, and unmethylated CpG oligonucleotides [31–33],”
BackgroundRole of Jak Kinases and STATs in Cytokine Signal Transduction
Leonard, W. J. (2001) · International Journal of Hematology · doi:10.1007/bf02981951 · Cited by 215 · cited 1×
“Phosphorylated STATs form transcription factors and activate transcription of appropriate genes [63].”
BackgroundYu, P., Steel, J. C., Zhang, M., Morris, J. C., & Waldmann, T. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1966 · Cited by 213 · cited 3×
“4 (CTLA-4) [122].”
BackgroundMethodInfluence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Noguchi, Y., Richards, E. C., Chen, Y. T., & Old, L. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2219 · Cited by 212 · cited 1×
“Peptide vaccine Mice Meth A sarcoma [77]”
Tagaya, Y., Kurys, G., Thies, T. A., Losi, J. M., Azimi, N., Hanover, J. A., Bamford, R. N., & Waldmann, T. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14444 · Cited by 209 · cited 1×
“peptides, containing either a 21-aa short or 48-aa long signal peptide [34,37].”
BackgroundNatural mechanisms protecting against cancer
Jakóbisiak, M., Lasek, W., & Gołąb, J. (2003) · Immunology Letters · doi:10.1016/j.imlet.2003.08.005 · Cited by 206 · cited 1×
“Due to bridging the innate and adaptive immunity and potently stimulating the production of IFN-γ—a cytokine coordinating natural mechanisms of anticancer defense [3]—IL-12 seemed ideal candidate for tumor immunotherapy in humans.”
BackgroundSelf-citationRosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0282 · Cited by 206 · cited 1×
“The therapy induced specific antitumor response and disease stabilization in the majority of patients [173] and, when applied following autologous stem cell transplantation, resulted in the marked development of myeloma-specific T cells and eradication of posttransplant residual disease in some patients [174].”
BackgroundInfluentialDubois, S., Patel, H. J., Zhang, M., Waldmann, T. A., & Müller, J. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2099 · Cited by 205 · cited 4×
“Advantages of IL-15 in tumor immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells [10–12] and CD8 T cells [13–16], and promoting a persistent immune response through its action on memory T cells [16–20].”
BackgroundInfluentialImmune-suppressive properties of the tumor microenvironment
Becker, J. C., Andersen, M. H., Schrama, D., & thor Straten, P. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1434-6 · Cited by 204 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundKikuchi, T., Akasaki, Y., Abe, T., Fukuda, T., Saotome, H., Ryan, J. L., Kufe, D. W., & Ohno, T. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00005 · Cited by 204
Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1393 · Cited by 201 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundMunger, W., Dejoy, S. Q., Jeyaseelan, R., Torley, L. W., Grabstein, K. H., Eisenmann, J., Paxton, R., Cox, T., Wick, M. M., & Kerwar, S. S. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1216 · Cited by 200 · cited 2×
“[21] and less effective in inducing Treg cell activity, as compared with IL-2 [22], and in certain circumstances it can even protect human effector T cells from the action of Treg cells [23] (see below).”
BackgroundIL-7 regulates basal homeostatic proliferation of antiviral CD4 + T cell memory
Lenz, D. C., Kurz, S. K., Lemmens, E., Schoenberger, S. P., Sprent, J., Oldstone, M. B. A., & Homann, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400640101 · Cited by 197 · cited 1×
“cytokine [102].”
Sanjabi, S., Mosaheb, M. M., & Flavell, R. A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.020 · Cited by 190
Bamford, R. N., DeFilippis, A. P., Azimi, N., Kurys, G., & Waldmann, T. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4418 · Cited by 189
Pérarnau, B., Saron, M.-F., San Martin, B. R., Bervas, N., Ong, H., Soloski, M. J., Smith, A. G., Ure, J. M., Gairin, J. E., & Lemonnier, F. A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199904)29:04<1243::aid-immu1243>3.0.co;2-a · Cited by 186
Heemskerk, M. H. M., Hoogeboom, M., Hagedoorn, R., Kester, M. G. D., Willemze, R., & Falkenburg, J. H. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031110 · Cited by 183 · cited 1×
“evasion strategies preventing their effective use in adoptive tumor therapy, patients’ T cells can be activated against potent viral or transplantation antigens and then redirected by transfecting them with genes encoding T cell receptors recognizing TAA [137,138].”
BackgroundRegulation of IL-15 secretion via the leader peptide of two IL-15 isoforms
Onu, A., Pohl, T., Krause, H., & Bulfone-Paus, S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.1.255 · Cited by 180 · cited 3×
“Following removal of signal peptide, mature IL-15 proteins are identical [34].”
BackgroundIL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15950 · Cited by 180
Casetti, R., Agrati, C., Wallace, M., Sacchi, A., Martini, F., Martino, A., Rinaldi, A., & Malkovsky, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901334 · Cited by 177
Sandau, M. M., Schluns, K. S., Lefrancois, L., & Jameson, S. C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6537 · Cited by 175
Amount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C. C., & Stoppacciaro, A. (1996) · PubMed · Cited by 174
Robertson, M. J., Cameron, C. A., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., & Ritz, J. (1999) · PubMed · Cited by 171
Nasu, Y., Bangma, C. H., Hull, G. W., Lee, H.-M., Hu, J., Wang, J., McCurdy, M. A., Shimura, S., Yang, G., Timme, T. L., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300834 · Cited by 170 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundImmunocytokines: a novel class of potent armed antibodies
Pasche, N., & Neri, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.007 · Cited by 169 · cited 1×
“Such biotherapeutics, called immunocytokines, tend to accumulate in the tumor tissue and, by releasing cytokines, directly kill tumor cells or induce a strong inflammatory process eliciting antitumor response [181].”
BackgroundNKG2D ligands: unconventional MHC class I‐like molecules exploited by viruses and cancer
Cerwenka, A., & Lanier, L. L. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00070.x · Cited by 167 · cited 1×
“cells, virus-infected cells, and tumor cells [116].”
IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro
Alves, N. L., Hooibrink, B., Arosa, F. A., & van Lier, R. A. W. (2003) · Blood · doi:10.1182/blood-2003-01-0183 · Cited by 167 · cited 3×
“Advantages of IL-15 in tumor immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells [10–12] and CD8 T cells [13–16], and promoting a persistent immune response through its action on memory T cells [16–20].”
BackgroundEpardaud, M., Elpek, K. G., Rubinstein, M. P., Yonekura, A.-R., Bellemare-Pelletier, A., Bronson, R., Hamerman, J. A., Goldrath, A. W., & Turley, S. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0045 · Cited by 167 · cited 2×
“Pre-association of IL-15 with IL-15Ra [52,53,124] or 15Ra-IgG1-Fc [12]”
BackgroundTrinchieri, G., Wysocka, M., D'Andrea, A., Rengaraju, M., Aste-Amezaga, M., Kubin, M., Valiante, N. M., & Chehimi, J. (1992) · Progress in Growth Factor Research · doi:10.1016/0955-2235(92)90016-b · Cited by 166 · cited 1×
“1): increasing production of IFN-γ, which is the most potent mediator of IL-12 actions, from NK and T cells [26]; stimulation of growth and cytotoxicity of activated NK cells, CD8+ and CD4+ T cells [27], shifting differentiation of CD4+ Th0 cells toward the Th1 phenotype [28]; enhancement of antibody-dependent cellula…”
BackgroundSun, Y., Jurgovsky, K., Möller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., & Schadendorf, D. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300619 · Cited by 164
Ansell, S. M., Witzig, T. E., Kurtin, P. J., Sloan, J. A., Jelinek, D. F., Howell, K. G., Markovic, S. N., Habermann, T. M., Klee, G. G., Atherton, P. J., et al. (2002) · Blood · doi:10.1182/blood.v99.1.67 · Cited by 164 · cited 2×
“The efficacy of IL-12 for the treatment for patients with recurrent B-cell non-Hodgkin’s lymphoma was also tested in combination with rituximab with the hope that due to the strong stimulatory effect of IL-12 on NK cells, this cytokine would potentiate antibody-dependent cellmediated cytotoxicity (ADCC) of rituximab […”
BackgroundResultIL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215950 · Cited by 164
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
Bajetta, E., Vecchio, M. D., Mortarini, R., Nadeau, R., Rakhit, A. K., Rimassa, L., Fowst, C., Borri, A., Anichini, A., & Parmiani, G. (1998) · PubMed · Cited by 163
Jonuleit, H., Wiedemann, K., Müller, G., Degwert, J., Hoppe, U., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2610 · Cited by 159 · cited 1×
“cells, but not T cells ([27,28] and reviewed in [24]).”
BackgroundChmielewski, M. M., & Abken, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1202-z · Cited by 157 · cited 1×
“Another therapeutic approach awaiting optimization in animal models and resuming in clinical trials is targeting IL-12 to the tumor environment and controlling its local production using chimeric antigen receptor (CAR)-modified T cells engineered with IL-12 gene [184].”
MethodNovel Human Interleukin-15 Agonists
Zhu, X., Marcus, W. D., Xu, W., Lee, H.-I., Han, K., Egan, J. O., Yovandich, J. L., Rhode, P. R., & Wong, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901244 · Cited by 155 · cited 2×
“One of the amino acid substitutions of asparagine residue at position 72 of human IL-15 produced mutein with improved binding to IL-2/15Rb-chain and 4-/5-fold increase in biological activity [123].”
BackgroundHeinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J., Elzaouk, L., Pavlovic, J., & Moelling, K. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.35 · Cited by 154 · cited 1×
“1 3 However, in clinical trials, results were mostly disappointing [163, 164], related, among others, to low gene transfer efficiency.”
BackgroundPeterson, A. C., Harlin, H., & Gajewski, T. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.144 · Cited by 153 · cited 3×
“adjacent to immunization site Melanoma [139]”
KELSALL, B. L., STÜBER, E., NEURATH, M., & STROBER, W. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb52660.x · Cited by 152
Minami, Y., Nakagawa, Y., Kawahara, A., Miyazaki, T., Sada, K., Yamamura, H., & Taniguchi, T. (1995) · Immunity · doi:10.1016/1074-7613(95)90081-0 · Cited by 150
Ahmed, M. B., Belhadj Hmida, N., Moes, N., Buyse, S., Abdeladhim, M., Louzir, H., & Cerf-Bensussan, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801792 · Cited by 148
Gollob, J., Veenstra, K. G., Parker, R. A., Mier, J. W., McDermott, D. F., Clancy, D., Tutin, L., Koon, H. B., & Atkins, M. B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.119 · Cited by 148 · cited 1×
“Melanoma, renal cancer [44, 141]”
Interleukin-15 (IL-15) Induces IL-8 and Monocyte Chemotactic Protein 1 Production in Human Monocytes
Badolato, R., Ponzi, A. N., Millesimo, M., Notarangelo, L. D., & Musso, T. (1997) · Blood · doi:10.1182/blood.v90.7.2804 · Cited by 146
Pützer, B. M., Hitt, M., Muller, W. J., Emtage, P. C. R., Gauldie, J., & Graham, F. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10889 · Cited by 146
Zhang, M., Yao, Z., Dubois, S. P., Ju, W., Müller, J. R., & Waldmann, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902637106 · Cited by 144 · cited 7×
“of IL-2 is also accompanied by severe toxicity [5,6].”
BackgroundMethodInfluentialMortier, E., Bernard, J., Plet, A., & Jacques, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1681 · Cited by 143 · cited 1×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundKang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S.-S., Lee, M. H., Park, K., Kim, K., Jeong, H. S., Kim, J.-A., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401300057388 · Cited by 135 · cited 1×
“IL-12-transduced autologous fibroblasts Peritumoral Melanoma and other cancers [144]”
BackgroundKobayashi, N., Kono, T., Hatakeyama, M., Minami, Y., Miyazaki, T., Perlmutter, R. M., & Taniguchi, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4201 · Cited by 134 · cited 1×
“and LYN [64,65].”
IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook, A. H., Kubin, M. Z., Cassin, M., Vonderheid, E. C., Vowels, B. R., Wolfe, J. T., Wolf, S. F., Singh, A., Trinchieri, G., & Lessin, S. R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1491 · Cited by 132 · cited 1×
“The rationale for testing the efficacy of IL-12 in patients with CTCL was the depressed function of Th1 cells and deficient production of IFN-γ in these patients, the possibility of subcutaneous and intralesion application of IL-12, and a relative susceptibility of this type of neoplasia to immune response-modifying a…”
BackgroundInterleukin-15 (IL-15) Induces NF-κB Activation and IL-8 Production in Human Neutrophils
McDonald, P. P., Russo, M. P., Ferrini, S., & Cassatella, M. A. (1998) · Blood · doi:10.1182/blood.v92.12.4828 · Cited by 131
Erratum To: Identification of a novel receptor/signal transduction pathway for IL‐15/T in mast cells
Tagaya, Y., Burton, J. D., Miyamoto, Y., & Waldmann, T. A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.6 · Cited by 130 · cited 1×
“instead of JAK1/3 and STAT3/5 [62].”
Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L. H., Avigan, D., Anderson, K. C., Ohno, T., & Kufe, D. W. (2002) · Blood · doi:10.1182/blood.v99.7.2512 · Cited by 129 · cited 1×
“Investigators expect that, like in experimental animal models, supplementation of IL-12 will promote, on the one hand, antitumor Th1 polarization and, on the other hand, will attenuate immunosuppressive activity of Treg cells [175, 176].”
MethodMinami, Y., Kono, T., Yamada, K., Kobayashi, N., Kawahara, A., Perlmutter, R. M., & Taniguchi, T. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05710.x · Cited by 128
Motzer, R. J., Rakhit, A. K., Thompson, J. A., Nemunaitis, J. J., Murphy, B. A., Ellerhorst, J. A., Schwartz, L. H., Berg, W. J., & Bukowski, R. M. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001750169934 · Cited by 127 · cited 1×
“Due to the low response to IL-12 and its high toxicity, accrual to some trials was even stopped [157].”
BackgroundNowicki, A., Szenajch, J., Ostrowska, G., Wojtowicz, A., Wojtowicz, K., Kruszewski, A. A., Maruszynski, M., Aukerman, S. L., & Wiktor-Jedrzejczak, W. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960103)65:1<112::aid-ijc19>3.0.co;2-i · Cited by 126
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates
Lugli, E., Goldman, C. K., Perera, L. P., Smedley, J., Pung, R., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Roederer, M. (2010) · Blood · doi:10.1182/blood-2010-03-275438 · Cited by 125 · cited 1×
“Both effector and central memory CD8 T cells are stimulated by IL-15 [18–20,98].”
BackgroundKaspar, M., Trachsel, E., & Neri, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0283 · Cited by 124 · cited 1×
“Augmentation of selectivity and antitumor effects should also be achieved through its antibody-mediated targeting to tumor vasculature [125].”
BackgroundIL-1β induces dendritic cells to produce IL-12
Wesa, A. K., & Galy, A. (2001) · International Immunology · doi:10.1093/intimm/13.8.1053 · Cited by 124 · cited 1×
“, by IL-1β [16]) or direct cell–cell contact with other immune cells (e.”
BackgroundMartinet, O., Ermekova, V., Qiao, J. Q., Sauter, B., Mandeli, J., Chen, L., & Chen, S. H. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.931 · Cited by 122 · cited 1×
“CD137 ligand 10 in adenoviral vector; intratumoral injection MCA26 colon carcinoma IL-12 in adenoviral vector; intratumoral injection [115]”
MethodZambello, R., Facco, M., Trentin, L., Sancetta, R., Tassinari, C., Perin, A., Milani, A. M., Pizzolo, G., Rodeghiero, F., Agostini, C., et al. (1997) · Blood · doi:10.1182/blood.v89.1.201 · Cited by 122
Osaki, T., Hashimoto, W., Gambotto, A. A., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., & Tahara, H. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300908 · Cited by 121 · cited 1×
“IL-18 Mice MCA205 fibrosarcoma [67]”
Kuhn, C., Hurwitz, S. A., Kumar, M. G., Cotton, J. P., & Spandau, D. F. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990129)80:3<425::aid-ijc15>3.0.co;2-7 · Cited by 120 · cited 1×
“vaccine (IL-2-transduced tumor cells) Mice TSA mammary adenocarcinoma SR-B10A glioma [75] [76]”
BackgroundNars, M. S., & Kaneno, R. (2013) · International Journal of Cancer · doi:10.1002/ijc.27801 · Cited by 120 · cited 1×
“Nevertheless, several chemotherapeutics, for example cyclophosphamide, paclitaxel, 5-fluorouracil, 5-aza-2′deoxycitidine, mitomycin, doxorubicin, and mitoxantrone, have been shown to demonstrate improved antitumor activity in mice when combined with immunotherapy ([65], for review, see [78, 79]).”
BackgroundAvigan, D. E., Vasir, B., George, D. J., Oh, W. K., Atkins, M. B., McDermott, D. F., Kantoff, P. W., Figlin, R. A., Vasconcelles, M. J., Xu, Y., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de4ce8 · Cited by 119
Portielje, J. E. A., Kruit, W. H. J., Schüler, M., Beck, J., Lamers, C. H., Stoter, G., Huber, C. H., de Boer-Dennert, M. M., Rakhit, A. K., Bolhuis, R. L. H., et al. (1999) · PubMed · Cited by 118
A Role for the Interferon‐Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin‐12
Angiolillo, A. L., Sgadari, C., & Tosato, G. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb52664.x · Cited by 116 · cited 1×
“These are potent antiangiogenic effects via induction of antiangiogenic cytokine and chemokine production [32], remodeling of the peritumoral extracellular matrix and tumor stroma [33], reprogramming of myeloid-derived suppressor cells [34], and changes in processing and increasing expression of MHC class I molecules…”
BackgroundPortielje, J. E. A., Lamers, C. H. J., Kruit, W. H. J., Sparreboom, A., Bolhuis, R. L. H., Stoter, G., Huber, C., & Gratama, J. W. (2003) · PubMed · Cited by 116
Kurys, G., Tagaya, Y., Bamford, R., Hanover, J. A., & Waldmann, T. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002373200 · Cited by 115 · cited 1×
“and is regulated at the level of translation, intracellular trafficking, and secretion [34–36].”
BackgroundActivity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Little, R. F., Pluda, J. M., Wyvill, K. M., Rodriguez-Chavez, I. R., Tosato, G., Catanzaro, A. T., Steinberg, S. M., & Yarchoan, R. (2006) · Blood · doi:10.1182/blood-2005-11-4455 · Cited by 114 · cited 2×
“Like in the previous study [156], the patients received independently highly active antiretroviral therapy (HAART).”
MethodResultDual-specific T cells combine proliferation and antitumor activity
Kershaw, M. H., Westwood, J. A., & Hwu, P. (2002) · Nature Biotechnology · doi:10.1038/nbt756 · Cited by 114 · cited 1×
“evasion strategies preventing their effective use in adoptive tumor therapy, patients’ T cells can be activated against potent viral or transplantation antigens and then redirected by transfecting them with genes encoding T cell receptors recognizing TAA [137,138].”
BackgroundGajewski, T. F., Fallarino, F., Ashikari, A., & Sherman, M. E. (2001) · PubMed · Cited by 113
Zeh, H. J., Hurd, S., Storkus, W. J., & Lotze, M. T. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199308000-00012 · Cited by 113
Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial
Mahvi, D. M., Henry, M. B., Albertini, M. R., Weber, S. M., Meredith, K. L., Schalch, H., Rakhmilevich, A. L., Hank, J. A., & Sondel, P. M. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701064 · Cited by 112 · cited 1×
“1 3 However, in clinical trials, results were mostly disappointing [163, 164], related, among others, to low gene transfer efficiency.”
BackgroundKishida, T., Asada, H., Itokawa, Y., Cui, F.-D., Shin‐Ya, M., Gojo, S., Yasutomi, K., Ueda, Y., Yamagishi, H., Imanishi, J., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00222-3 · Cited by 112 · cited 3×
“mice synergistically augmented antitumor immune response with complete regression of lymphomas in 80% of animals [129].”
BackgroundMethodAddison, C., Bramson, J. L., Hitt, M., Muller, W., Gauldie, J., & Graham, F. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300731 · Cited by 112 · cited 8×
“Classical examples of such cytokines are TNF-α [45, 46], IL-2 [47, 48], IL-15 [49, 50], IL-18 [50, 51], or GM-CSF [52].”
BackgroundMethodInfluentialParihar, R., Nadella, P., Lewis, A., Jensen, R., De Hoff, C., Dierksheide, J. E., VanBuskirk, A. M., Magro, C. M., Young, D. C., Shapiro, C. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0265 · Cited by 111 · cited 1×
“Breast, pancreas, cervical cancer [134]”
Effect ofmts1 (S100A4) expression on the progression of human breast cancer cells
Grigorian, M., Ambartsumian, N. S., Lykkesfeldt, A. E., Bastholm, L., Elling, F., Georgiev, G. P., & Lukanidin, E. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960917)67:6<816::aid-ijc10>3.0.co;2-# · Cited by 108
Anwer, K., Barnes, M. N., Fewell, J. G., Lewis, D. H., & Alvarez, R. D. (2009) · Gene Therapy · doi:10.1038/gt.2009.159 · Cited by 108 · cited 2×
“However, these encouraging data must be interpreted with caution not only due to the small sample size and possible selection bias but also because of additional treatment (chemotherapy) of some patients [161].”
BackgroundTim-3 Negatively Regulates IL-12 Expression by Monocytes in HCV Infection
Zhang, Y., Cheng, J., Wang, J. M., Xiao, J., Wu, X. Y., Jia, Z., Moorman, J. P., & Yao, Z. Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019664 · Cited by 107 · cited 2×
“Another suppressive molecule is T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), which can inhibit the production of IL-12 by dendritic cells [15] within a tumor environment (highlighted in [22]).”
BackgroundInfluentialBekaii-Saab, T. S., Roda, J. M., Guenterberg, K. D., Ramaswamy, B., Young, D. C., Ferketich, A. K., Lamb, T. A., Grever, M. R., Shapiro, C. L., & Carson, W. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0820 · Cited by 107 · cited 1×
“[131], who showed additionally that the source of continuously produced IFN-γ was CD56+ (NK) cells but not T cells.”
BackgroundRudman, S. M., Jameson, M. B., McKeage, M. J., Savage, P., Jodrell, D. I., Harries, M., Acton, G., Erlandsson, F., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2490 · Cited by 107 · cited 1×
“[182], an immunocytokine AS1409 targeting extra-domain B (eD-B) fibronectin isoform was used to deliver IL-12 into tumor mass in a small group of 13 patients with melanoma and renal cell carcinoma.”
MethodULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Sutherland, C. L., Rabinovich, B., Chalupny, N. J., Brawand, P., Miller, R., & Cosman, D. (2006) · Blood · doi:10.1182/blood-2005-11-011320 · Cited by 106 · cited 1×
“As one of the tumor evasion strategies relies on shedding soluble MIC ligands that down-regulate expression of the NKG2D receptor on effector cells [117], it is fair to assume that IL-15, capable of restoring”
BackgroundYounes, A., Pro, B., Robertson, M. J., Flinn, I. W., Romaguera, J. E., Hagemeister, F., Dang, N. H., Fiumara, P., Loyer, E. M., Cabanillas, F. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0540 · Cited by 106 · cited 1×
“In the same study, ten patients with relapsed Hodgkin’s disease were also included [153].”
BackgroundWysocka, M., Benoit, B. M., Newton, S. B., Azzoni, L., Montaner, L. J., & Rook, A. H. (2004) · Blood · doi:10.1182/blood-2004-03-1190 · Cited by 104 · cited 3×
“motifs binding Toll-like receptors [144].”
BackgroundInfluentialLenzi, R., Rosenblum, M. G., Verschraegen, C. F., Kudelka, A. P., Kavanagh, J. J., Hicks, M. E., Lang, E., Nash, M. A., Levy, L. B., Garcia, M. E., et al. (2002) · PubMed · Cited by 103
Emtage, P. C. R., Wan, Y., Hitt, M., Graham, F. L., Muller, W. J., Zlotnik, A., & Gauldie, J. (1999) · Human Gene Therapy · doi:10.1089/10430349950018463 · Cited by 103 · cited 2×
“Lymphotactin in adenoviral vector; intratumoral injection PyMT- or Neu-expressing mammary adenocarcinoma IL-12 in adenoviral vector; intratumoral injection [112]”
BackgroundEvans, R., Fuller, J. A., Christianson, G. J., Krupke, D. M., & Troutt, A. B. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1132 · Cited by 102
The roles of interleukin-15 receptor α: Trans-presentation, receptor component, or both?
Schluns, K. S., Stoklasek, T. A., & Lefrançois, L. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.02.017 · Cited by 99 · cited 1×
“IL-15 is not usually secreted in a soluble form [49] and is rarely”
BackgroundInterleukin-7 or Interleukin-15 Enhances Survival of Mycobacterium tuberculosis-Infected Mice
Maeurer, M. J., Trinder, P., Hommel, G., Walter, W., Freitag, K., Atkins, D., & Störkel, S. (2000) · Infection and Immunity · doi:10.1128/iai.68.5.2962-2970.2000 · Cited by 99 · cited 1×
“By inducing the release of chemokines from monocytes it attracts inflammatory cells [78] and increases the ability of macrophages to eliminate bacteria [79] and parasites [80].”
BackgroundHeinzerling, L., Feige, K., Rieder, S., Akens, M. K., Dummer, R., Stranzinger, G., & Moelling, K. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090000165 · Cited by 98 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundBadoual, C., Bouchaud, G., Agueznay, N. E. H., Mortier, E., Hans, S., Gey, A., Fernani, F., Peyrard, S., -Puig, P. L., Bruneval, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6842 · Cited by 98 · cited 1×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundCrystal Structure of the Interleukin-15·Interleukin-15 Receptor α Complex
Olsen, S. K., Ota, N., Kishishita, S., Kukimoto‐Niino, M., Murayama, K., Uchiyama, H., Toyama, M., Terada, T., Shirouzu, M., Kanagawa, O., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706150200 · Cited by 97 · cited 3×
“Cis-presentation, when IL-15 from autocrine or other sources is presented by IL-15Ra to IL-15R on the same cell, is also possible [42].”
BackgroundSurvival of women with breast cancer in Europe: Variation with age, year of diagnosis and country
Sant, M., Capocaccia, R., Verdecchia, A., Estève, J., Gatta, G., Micheli, A., Coleman, M. P., Berrino, F., & The EUROCARE Working Group (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980831)77:5<720::aid-ijc10>3.0.co;2-5 · Cited by 97
Dai, Z., Arakelov, A., Wagener, M. E., Konieczny, B. T., & Lakkis, F. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.6.3131 · Cited by 97 · cited 1×
“cells [8] and the induction of activation-induced cell death of effector T lymphocytes [9].”
BackgroundChapoval, A. I., Fuller, J. A., Kremlev, S. G., Kamdar, S. J., & Evans, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6977 · Cited by 96 · cited 3×
“It prolonged remission induced by cyclophosphamide in rhabdomyosarcoma-bearing mice [132,133] with participation of Tab, Tgd cells, and NK cells [132].”
BackgroundFunctions of γC cytokines in immune homeostasis: Current and potential clinical applications
Overwijk, W. W., & Schluns, K. S. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.03.512 · Cited by 94
Rubinstein, M. P., Kadima, A. N., Salem, M. L., Nguyen, C. L., Gillanders, W. E., & Cole, D. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4928 · Cited by 93 · cited 3×
“Combined use with TAA-pulsed DC vaccine [149]”
Background
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.